Oncotelic Therapeutics, Inc. (OTLC): Total Assets
$393.09M
As of 2025-12-31
$394.75M
As of 2026-06-30
+121.6%
3-year compound annual growth
+75.4%
5-year compound annual growth
+30.5%
10-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $393.09M | n/m | 2026-04-15, Balance as of period end |
| 2024-12-31 | $26.68M | -11.1% | 2026-04-15, Balance as of period end |
| 2023-12-31 | $30.01M | -16.9% | 2025-04-15, Balance as of period end |
| 2022-12-31 | $36.12M | +53.0% | 2024-04-12, Balance as of period end |
| 2021-12-31 | $23.61M | -0.2% | 2023-04-20, Balance as of period end |
| 2020-12-31 | $23.66M | -0.1% | 2022-04-15, Balance as of period end |
| 2019-12-31 | $23.68M | +762.0% | 2021-04-15, Balance as of period end |
| 2018-12-31 | $2.75M | +134.5% | 2020-05-14, Balance as of period end |
| 2017-12-31 | $1.17M | -91.7% | 2019-04-10, Balance as of period end |
| 2016-12-31 | $14.11M | -48.6% | 2018-04-17, Balance as of period end |
| 2015-12-31 | $27.45M | -9.8% | 2017-03-30, Balance as of period end |
| 2014-12-31 | $30.42M | +317.1% | 2016-03-25, Balance as of period end |
| 2013-12-31 | $7.29M | +33.9% | 2015-03-30, Balance as of period end |
| 2012-12-31 | $5.45M | -50.7% | 2014-03-20, Balance as of period end |
| 2011-12-31 | $11.06M | +98.6% | 2013-03-15, Balance as of period end |
| 2010-12-31 | $5.57M | n/a | 2012-03-28, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Oncotelic Therapeutics, Inc. (OTLC) | 2025-12-31 | $393.09M | n/m |
| Erasca, Inc. (ERAS) | 2025-12-31 | $396.15M | -21.2% |
| Ironwood Pharmaceuticals Inc (IRWD) | 2025-12-31 | $396.90M | +13.1% |
| Tango Therapeutics, Inc. (TNGX) | 2025-12-31 | $398.69M | +26.0% |
| Harrow, Inc. (HROW) | 2025-12-31 | $399.48M | +2.7% |
| MBX Biosciences, Inc. (MBX) | 2025-12-31 | $385.14M | +43.4% |
| Zenas BioPharma, Inc. (ZBIO) | 2025-12-31 | $383.64M | +3.7% |
| Xeris Biopharma Holdings, Inc. (XERS) | 2025-12-31 | $383.53M | +18.7% |
| Nkarta, Inc. (NKTX) | 2025-12-31 | $404.21M | -19.4% |
Compare OTLC, ERAS, IRWD, TNGX side by side · Screen every company in Pharmaceutical Preparations ↗